Skip to Main Content

Multiple Myeloma and Gammopathies Program

Annually, approximately 32,000 new patients are diagnosed with multiple myeloma, a cancer of a type of white blood cell, or plasma cell. Overall survival in patients with myeloma has shown improvement in recent years, with new treatments approved by the FDA as recently as this year. Yale Cancer Center and Smilow Cancer Hospital have several clinical trials available for patients with myeloma in need of new options, or looking to receive the latest treatment advances.

The treatment of multiple myeloma is usually given in phases and depends on the overall health and age of a patient at diagnosis. Induction therapy is used to reduce the amount of disease, followed by consolidation therapy to maximize response to treatment and reduce any remaining cancer cells. Maintenance therapy is administered after the initial treatment to help keep the disease well controlled. Autologous stem cell transplant, where patients serve as their own donor, is another treatment commonly used to treat multiple myeloma. When receiving therapy for multiple myeloma, you will be cared for by an expert, multidisciplinary team which can include your hematologist focused on the treatment of myeloma and related diseases, stem cell transplant specialists, pathologists, and radiation oncologist, among other providers.

The CAR T-Cell Therapy Program at Smilow Cancer Hospital brings innovative immunotherapy treatment options to patients with certain blood cancers. For adults with relapsed or refractory multiple myeloma, an FDA approved therapy ABECMA is available which uses a patient’s own T-cells to help fight myeloma. This is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma and is currently available at Smilow Cancer Hospital. Ongoing research and clinical trials in the field continue to provide patients with new options for care.



Contact
Smilow Multiple Myeloma and Gammopathies Program
Yale New Haven Hospital North Haven Medical Center
6 Devine Street, 4th floor
North Haven, CT 06473

Phone: 203-200-4363

Program Members

  • Assistant Professor of Medicine (Hematology)

    Noffar Bar, MD, is an Assistant Professor of Medicine (Hematology) at Yale School of Medicine and completed her internship and residency at the Mount Sinai Hospital and her fellowship at Yale. She received her medical degree from the Sackler School of Medicine New York State/American Program of Tel Aviv University. Dr. Bar is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the International Myeloma Society. Dr. Bar’s research is focused on multiple myeloma and other plasma cell disorders. She specializes in all treatment modalities for myeloma including CAR T-cell therapy and stem cell transplant. She received grant support through the Conquer Cancer Foundation’s Young Investigator Award for her work looking at the prevention of multiple myeloma. Dr. Bar is dedicated to improving treatments for myeloma patients through innovative clinical trials. Additionally, Dr. Bar is a medical educator and a member of the Classical Hematology Disease team at Yale. She is interested in promoting high value care for hematology patients.
  • Assistant Professor of Medicine (Hematology)

    Dr. Sabrina Browning received her medical degree from the University of Connecticut School of Medicine where she first confirmed her passion for caring for individuals with hematologic diseases. Her internship and residency were completed at Yale New Haven Hospital. After residency, Dr. Browning served as Amyloid Fellow at the internationally recognized Amyloidosis Center at Boston University School of Medicine and Boston Medical Center. In this position, she played a key role in the multidisciplinary care of and coordination for patients with immunoglobulin light chain (AL) amyloidosis and related diseases. She returned to Yale New Haven Hospital to complete her fellowship in Medical Oncology and Hematology. Upon joining as faculty in the Hematology section at Yale School of Medicine, Dr. Browning was the sole awardee of the Bernard Forget Scholarship for 2020-2021, which supports deserving individuals who are transitioning into an academic career in Hematology. Dr. Browning is a physician in the Smilow Multiple Myeloma and Gammopathies Programs and also sees patients in the Classical Hematology Clinic and she is incredibly passionate about the comprehensive management of patients with rare hematologic disorders including AL amyloidosis and hereditary hemorrhagic telangiectasia or HHT. Dr. Browning’s clinical and research interests include evaluating new treatments for multiple myeloma, AL amyloidosis, and other hematologic diseases and their impact on outcomes and quality of life for patients. With the support of the Frederick DeLuca Foundation and the DeLuca Center for Innovation in Hematology Research, she is also studying the association between metabolic syndrome, which can include obesity, high blood pressure, high cholesterol, and diabetes, and the development of monoclonal gammopathy and multiple myeloma with the aim to learn more about potential preventative strategies. Dr. Browning has a clinical and research interest in the management of issues such as bleeding and clotting in individuals with multiple myeloma and AL amyloidosis. Dr. Browning serves as the Principal Investigator on several clinical trials here at Yale for patients with multiple myeloma and AL amyloidosis and is interested in design of new clinical trials to further help her patients and others living with these diseases. Dr. Browning serves as the representative for the Yale Cancer Center on the Faculty Advisory Council for Yale School of Medicine. She is a member of the American Society of Hematology (ASH), the International Myeloma Society (IMS), and the International Society of Amyloidosis (ISA). As a member of the HHT center here at Yale she is also a registered physician with CureHHT. Dr. Browning is dedicated to providing patient-centered and compassionate care to individuals and their families through a team-based approach. She is also committed to teaching trainees at various levels of medical training.
  • Associate Professor of Internal Medicine (Hematology); Research Leader, Myeloma Program, Hematology

    Dr. Neparidze obtained her medical degree from Aieti Medical School in Tbilisi, Georgia in 2000. She subsequently completed Postdoctoral Research Fellowships at Emory, Northwestern and Yale Universities, followed by Internal Medicine Residency and Hematology/Medical Oncology Fellowship at Yale University. She has served as an assistant professor at Yale University School of Medicine, Medical Oncology/Hematology since 2012.  She specializes in multiple myeloma, monoclonal gammopathies, AL amyloidosis, Waldenstrom's macroglobulinemia and classical hematology. Dr. Neparidze is the research leader for the myeloma program, and her research focus is on monoclonal gammopathies, multiple myeloma, with specific interests in advanced imaging, tumor heterogeneity and mechanisms of tumor progression and resistance in myeloma, including advancing and developing novel therapies for multiple myeloma.Learn more about Dr. Neparidze>>
  • Assistant Professor of Medicine (Hematology); Assistant Medical Director, Smilow Cancer Hospital Care Center, North Haven

    Terri Parker, MD, is an Assistant Professor of Medicine at the Yale School of Medicine in the section of Hematology.  Dr. Parker completed her internal medicine residency at the University of Connecticut followed by a fellowship program in hospice and palliative medicine. She also completed a fellowship in hematology and medical oncology at Yale University School of Medicine. Dr. Parker serves as the assistant medical director at the Smilow Cancer Hospital Care Center in North Haven that is home to two hematology programs, classical hematology and the multiple myeloma and gammopathies program. She is a member of the protocol review committee (PRC) at the Yale Cancer Center, which is charged with the scientific evaluation of all cancer clinical protocols and amendments proposed at Yale prior to initiation. Dr. Parker currently serves as co-chair of the Multiple Myeloma Committee for ClinicalPath, which presents evidence-based oncology pathways to academic and community practices. Dr. Parker treats patients with plasma cell dyscrasias, including multiple myeloma and related diseases such as AL amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukemia, smoldering multiple myeloma, and Waldenstrom’s macroglobulinemia.  She has experience with clinical trials focused on novel therapies and drug combinations with a goal of advancing the standard of care for patients with AL amyloidosis, newly diagnosed and relapsed refractory multiple myeloma.  Learn more about Dr. Parker>>